Navigation Links
Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Date:7/8/2010

pportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain govern
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
2. Shire plc Appoints Two New Board Directors
3. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
4. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
5. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
8. Shire Supports Rare Disease Day 2010
9. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
10. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
11. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Brooklyn residents now have ... and chronic pain and injuries. Nunzio Saulle , ... grand opening of his NJS Physical Medicine and Rehabilitation ... on Thursday, March 5, 2015. Health Plus Management, LLC ... is located at 1178 Flatbush Avenue. This new PM&R ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biologics and Biosimilars ... , The Global Biologics and ... in-depth study on the current state of the ... provides a basic overview of the industry including ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 ... in Personalized Medicine, is excited to announce the ... Testing to Optimize the Management of Pain”. , ... at Medscape.com for the next year. The focus ... how to recognize inadequate pain treatments, integrate appropriate ...
(Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biologics and Biosimilars Industry Report 2015-2020 2Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3
... Aug. 7 Kensey Nash Corporation today announced an ... along with the trademark, inventory and other assets associated ... the terms of the agreement, the Company and Biomet ... agreement. Pursuant to the agreement, following a brief transition ...
... , , SAN MATEO, Calif., Aug. ... , , , Granted ... non-diabetic adults, either alone or in combination with other medicinal products for pain ... (Astellas) for commercialization of Qutenza in Europe, Middle East and Africa, including commercialization ...
... , , SAN MARINO, ... VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. ... University of Colorado Professor M. Karen Newell called "metabolic disruption ... to generate energy from glucose or from fatty acids. ...
Cached Biology Technology:Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... protein that helps pack DNA into the cell nucleus has ... researchers found that the protein, histone H1, also takes part ... all proteins are made. The study appeared online May ... A human cell,s genetic material is so vast that it ...
... of the extinction of woolly mammoths and other large mammals ... fallen victim to the same type of "trophic cascade" of ... the global decline of predators such as wolves, cougars, and ... originally begun by human disruption of ecosystems, a new study ...
Cached Biology News:CryoSat-2 exceeding expectations 2Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 2'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 4
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
... Varian 500-MS LC Ion Trap is ... LC/MS analysis where sensitivity, reliability and ... provides a robust platform for demanding ... resolution, and mass stability reflect the ...
... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
... General description: The Costar strip ejector is ... removal of Costar strips from their holder. ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ...
Biology Products: